Assessing the Level of N-terminal Pro-peptide of Type III Collagen in Patients with Chronic Heart Failure and Metabolic Syndrome

Drapkina Oxana¹, Zyatenkova Elena^2, and Ivashkin Vladimir²

¹National Research Center for Preventive Medicine, Moscow, Russian Federation

²The First Moscow Medical University named by I. M. Sechenov, Clinic of the propedutic of the internal disease, Moscow, Russian Federation

Cite this paper:
Drapkina Oxana, Zyatenkova Elena and Ivashkin Vladimir. Assessing the Level of N-terminal Pro-peptide of Type III Collagen in Patients with Chronic Heart Failure and Metabolic Syndrome. American Journal of Clinical Medicine Research. 2015; 3(3):50-54. doi: 10.12691/ajcmr-3-3-4

Abstract

The development and progression of heart failure accelerate obesity, disorders of carbohydrate and lipid metabolism. These states are united by the term "metabolic syndrome". The hepatic manifestation of the metabolic syndrome is a non-alcoholic fatty liver disease (NAFLD). The combination of NAFLD and cardiovascular disease leads to increased risk of cardiovascular complications and has a significant impact on the prognosis and outcome of CHF. A key factor in the pathogenesis and progression of CHF is myocardial remodeling. The metabolic products of collagen (N-terminal pro-peptide of type III collagen) are considered as promising candidates for markers of myocardial remodeling and development of heart failure. In a number of papers increased level of PIIINP is a predictor of cardiac mortality or rehospitalization due to decompensation of heart failure associated with an increased risk of death. Materials and Methods: The study group included 39 patients with CHF and MS. The control group included 38 patients with chronic heart failure, without the metabolic syndrome. In all patients the diagnosis of heart failure was confirmed by quality measuring the NT-proBNP. The severity of the clinical manifestations of heart failure, functional status of the patient were assessed. All patients underwent biochemical blood tests. The size of the heart chambers, wall thickness of the myocardium and epicardial fat were estimated by echocardiography. All the patients underwent the calculation of Fatty Liver Index, NAFLD Fibrosis Score. Results: The level of the main group PIIINP is 3,3 ± 1,5 g / l; in the control group - 2,3 ± 1,3 g / l (p = 0,00046). Statistical analysis revealed significant correlation (p<0.05) between laboratory data and PIIINP: the level of uric acid, glucose level, GFR, value FLI, NFS; between the data of echocardiography and PIIINP: thickness of epicardial fat, IVS thickness, LV myocardial mass, RA dimensions, LA, ESD LV, ratio E / A, ratio E / e. Conclusions: The use of PIIINP in clinical practice will identify patients with CHF and MS with structural and functional changes in the myocardium in the early stages of the disease. Also the determination of the level of PIIINP in patients with CHF and MS will allow identifying patients with liver disease and selecting the ones for further assessment and selection of therapy taking into consideration attendant pathology.

Keywords:
chronic heart failure metabolic syndrome fibrosis N-terminal pro-peptide of type III collagen non-alcoholic fatty liver disease Fatty Liver Index NAFLD Fibrosis Score non-invasive evaluation of hepatic steatosis non-invasive assessment of liver fibrosis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Belenkov Yu. N.; Mareev V. Yu.; Ageev F. T. and all. Etiologic causes of CHF development in the European part of the Russian Federation (hospital stage). Chronic heart failure. 2011; 12 (6): 333-338.
[2]	Belenkov Yu. N.; Mareev V. Yu.; Ageev F. T. and all. The first results of national epidemiological studies and epidemiological examination of patients with heart failure in clinical practice (for uptake) - EPOCHA-O-CHF. Chronic heart failure. 2003; 4 (3): 116-121.
[3]	Katz A.M. The “modern” view of heart failure: how did we get here? Circ. Heart Fail. 2008, 1, 63-71.
[4]	Sulimov V.A.; Napalkov D.A.; Seidov N.M. Chronic heart failure: a shift of focus in the initial stages of the disease. The attending physician. 2008; 4: 58-60.
[5]	Trifonov I.R. Characterization of cardiac binding protein fatty acid as a marker of myocardial necrosis in common clinical situations. Abstract of the thesis of the doctor of medical sciences. Moscow – 2009-50.
[6]	Allen L.A.; Felker G.; Michael,; Pocock Stuart; McMurrayet al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program // European Journal of Heart Failure. 2009: 11:170-177.
[7]	Solomakhina H.; Yu. Belenkov; V.Varshavsky "Fibrosis of myocardial systolic and diastolic congestive heart failure." M .: Medpraktika, 2014, 64 p.
[8]	Fan Dong; Abhijit Takawale; Jiwon Lee and Zamaneh Kassiri. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis & Tissue Repair 2012, 5:15.
[9]	Drapkina O.M.; Cherkunova E.V.; Evaluation of disorders of contractile function and atrial fibrosis as a predictor of chronic heart failure. Rational Pharmacotherapy in Cardiology. 2014; 10 (2). 231-237.
[10]	Lombardi R.; Betocchi S., Losi M.A.; Tocchetti C.G.; Aversa M.; Miranda M.; D’Alessndro G.; Cacaca A.; Chiampi Q.; Chiarello M. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation, 2003,108, 1455-1460.
[11]	Bedogni G.; Bellentani S.; Miglioli L. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006:6: 33.
[12]	Angulo P.; Hui J., Marchesini G. et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hepatology, Vol. 45, No. 4, 2007.
[13]	Tanwar S.; Trembling P.M.; Guha IN, et al. Validation of PIIINP for the detection and assessment of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Hepatology 2013; 57: 103-11.
[14]	Zannad F.; Alla F.; Dousset B.; Perez A.; Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation, 2000, 102, 2700-2706.
[15]	Cicoira M.; Rossi, A.; Bonapace, S.; Zanolla, L.; Golia, G.; Franceschini, L.; Caruso, B.; Marino, P.N.; Zardini, P. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J. Card. Fail., 2004, 10, 403-411.
[16]	Alberto С. Epicardial fat measured to the echocardiogram is correlated to carotid atherosclerosis. Rev. brasi. de ecocard. 24:16-22. 2012.
[17]	Bachar G.N. et al. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects. Am J Cardiol. 15;110:534-8. 2012.
[18]	lacobellis G.; Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab. 90:6300 - 2. 2005.
[19]	Antoniotti R.; Antonucci E.; Cremaschi G. Ultrafiltration in heart failure / Ital. Nefrol. – 2012. – № 29(5). – Р. 548-562.
[20]	Renal function and prediction of cardiovascular risk. Russian guidelines were developed by the Expert Committee of All-Russian Scientific Society of Cardiology and the Scientific Society of Nephrology Russia // 3 to the journal "Cardiovascular therapy and prevention» .- 2008. - № 7 (6). 41.
[21]	Quilliot D.; Alla F.; Bohme P. et al. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes Relat Metab Disord. 2005.
[22]	Drapkina O.M. Nonalcoholic fatty liver disease and metabolic syndrome. Consilium Medicum Gastroenterology №1 2008.
[23]	Drapkina O.M.; O.N. Korneeva; Drapkina Y.S. Rational Pharmacotherapy in Cardiology Issue number 3 / Volume 9/2013 pp 287-291.
[24]	Drapkina O.M.; Gatsolaeva D.S.; Ivashkin V.T. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Russian medical lead №2 2010, pp 72-78.
[25]	Ivashkin V.T.; O.M. Drapkina; O.N. Korneeva. Clinical variants of metabolic syndrome. MIA. M., - 2011. Pp 220.
[26]	Drapkina O.M.; Gegenava B.B. Myocardial fibrosis in patients with diabetes. Rational Pharmacotherapy in Cardiology, 2013, 9 (1), pp.58-61
[27]	Drapkina O.M.; Emelyanov A.V. Fibrosis and atrial fibrillation -Mechanism and treatment. Hypertension, 2013, №6, Volume 19, pp.487-495
[28]	Klappacher, G.; Franzen, P.; Haab, D.; Mehrabi, M.; Binder, M.; Plesch, K.; Pacher, R.; Grimm, M.; Pribill, I.; Eichler, H.G Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and inpacton diagnosis and prognosis. Am. J. Cardiol., 1995, 75, 913-918.